Originally published June 17. This article has been corrected from a previous version to reflect that Myriad is developing the HRD test to guide platinum-based treatment decisions, and does not plan to launch BRACAnalysis in this setting.

NEW YORK (GenomeWeb) – This fall Myriad Genetics is planning to launch BRACAnalysis as a companion test that can pick out which breast cancer patients have BRCA1 and BRCA2 mutations, and therefore will respond to the PARP inhibitor olaparib.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.